Search Results - "Yoshida, E.M."

Interferon‐Based Combination Anti‐Viral Therapy for Hepatitis C Virus After Liver Transplantation: A Review and Quantitative Analysis by Wang, C. S., Ko, H. H., Yoshida, E. M., Marra, C. A., Richardson, K.

“…Recurrence of hepatitis C virus (HCV) infection after liver transplantation (LT) is universal. However, the efficacy, tolerability and safety of combination…”
Get full text

The current state of liver transplantation in Canada by Yoshida, E.M, Thiele, S.L, Mason, A, Peltekian, K, Wong, P, Hux, M, Fischer, A, Borrelli, R

Get full text

Are DAAs reducing barriers for HIV co-infected and people who inject drugs? A population based cohort study by Janjua, N, Islam, N, Wong, J, Yoshida, E.M, Ramji, A, Samji, H, Butt, Z.A, Chong, M, Cook, D, Alvarez, M, Tyndall, M, Krajden, M

Get full text

Efficacy and safety of the fixed-dose combination regimen of MK3 [MK-3682/grazoprevir/ruzasvir] with or without ribavirin in non-cirrhotic or cirrhotic patients with chronic HCV GT1, 2, 3, 4 or 6 infection (Parts A & B of C-CREST-1 & 2) by Lawitz, E, Yoshida, E.M, Buti, M, Vierling, J.M, Almasio, P.L, Bruno, S, Ruane, P.J, Hassanein, T.I, Mullhaupt, B, Pearlman, B, Jancoriene, L, Gao, W, Huang, H.-C, Shepherd, A, Tannenbaum, B, Fernsler, D, Li, J.J, Grandhi, A, Liu, H, Su, M, Dutko, F, Yeh, W.W, Plank, R, Nguyen, B.-Y.T, Wahl, J, Barr, E, Butterton, J.R

Get full text

P0058 : Sofosbuvir-based antiviral therapy is highly effective in recurrent hepatitis c in liver transplant recipients: A “real-life” canadian multicenter experience by Faisal, N, Bilodeau, M, Aljudaibi, B, Peltekian, K, Yoshida, E.M, Hussaini, T, Ghali, P, Congly, S.E, Ma, M, Cooper, C, Selzner, N, Renner, E.L, Lilly, L.B

Get full text

High Efficacy of Ledipasvir/Sofosbuvir Plus Ribavirin among Patients with Decompensated Cirrhosis who Underwent Liver Transplant during Participation in the Solar-1 and -2 Studies by Müllhaupt, B, Kwo, P, Agarwal, K, Duvoux, C, Durand, F, Peck-Radosavljevic, M, Yoshida, E.M, Lilly, L, Willems, B, Vargas, H, Kumar, P, Brown, R.S, Horsmans, Y, De-Oertel, S, Arterburn, S, Dvory-Sobol, H, Brainard, D.M, McHutchison, J.G, Terrault, N, Rizzetto, M

Get full text

Trends in health care utilization and costs attributable to hepatocellular carcinoma, 2002-2009: a population-based cohort study by Thein, H H, Qiao, Y, Young, S K, Zarin, W, Yoshida, E M, de Oliveira, C, Earle, C C

“…The incidence of hepatocellular carcinoma (hcc) and the complexity of its diagnosis and treatment are increasing. We estimated trends in net health care…”
Get full text

O163 TURQUOISE-II: SVR12 RATES OF 92–96% IN 380 HEPATITIS C VIRUS GENOTYPE 1-INFECTED ADULTS WITH COMPENSATED CIRRHOSIS TREATED WITH ABT-450/R/ABT-267 AND ABT-333 PLUS RIBAVIRIN (3D+RBV) by Poordad, F, Hezode, C, Trinh, R, Kowdley, K.V, Zeuzem, S, Agarwal, K, Shiffman, M.L, Wedemeyer, H, Berg, T, Yoshida, E.M, Forns, X, Lovell, S.S, Da Silva-Tillmann, B, Campbell, A.L, Podsadecki, T

Get full text

P1129 EFFECT OF HCV GENOTYPE-1 SUBTYPE ON RESPONSE TO FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS: POOLED DATA FROM PHASE III TRIALS by Jacobson, I.M, Jensen, D.M, Dieterich, D, Sarrazin, C, Foster, G.R, Yoshida, E.M, Nelson, M, Ingiliz, P, Soriano, V, Cooper, C, Stern, J.O, Quinson, A.-M, Kukolj, G, Scherer, J, Drulak, M, Gallivan, J.-P, Schobelock, M, Ferenci, P

Get full text

61 TREATMENT WITH SOFOSBUVIR + RIBAVIRIN FOR 12 WEEKS ACHIEVES SVR12 OF 78% IN GT2/3 INTERFERON-INELIGIBLE, -INTOLERANT, OR -UNWILLING PATIENTS: RESULTS OF THE PHASE 3 POSITRON TRIAL by Jacobson, I, Yoshida, E.M, Sulkowski, M, Nelson, D.R, Svarovskaia, E, An, D, McNally, J, Brainard, D.M, Symonds, W.T, McHutchison, J.G, Pianko, S, Kowdley, K.V

Get full text

P1121 EARLY STOPPING RULES FOR FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS: EXPLORATORY STUDY OF POOLED DATA FROM PHASE III TRIALS by Ferenci, P, Dieterich, D, Zeuzem, S, Mantry, P, Sarrazin, C, Crespo, J, Tam, E, Dufour, J.-F, Yoshida, E.M, Nishiguchi, S, Bourlière, M, Omata, M, Abergel, A, Kuboki, M, Carvalho, A, Peng, C.-Y, Romero-Gómez, M, Wright, D, Stern, J.O, Böcher, W, Kukolj, G, Gallivan, J.-P, Scherer, J, Jensen, D.M

Get full text

428 ADHERENCE TO ASSIGNED DOSING REGIMEN AND SUSTAINED VIROLOGIC RESPONSE AMONG HEPATITIS C GENOTYPE 1 TREATMENT-NAIVE AND PEG/RIBAVIRIN TREATMENT-FAILURES TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN by Gordon, S.C, Lawitz, E.J, Bacon, B.R, Sulkowski, M.S, Yoshida, E.M, Davis, M, Boparai, N, Sniukiene, V, Burroughs, M, Brass, C.A, Albrecht, J.K, Reddy, K.R

Get full text

A case of recurrent pyogenic cholangitis by Krygier, D.S, Harris, A.C, Yoshida, E.M

Get full text

12 HIGH SVR12 WITH 16 WEEKS OF TEGOBUVIR AND GS-9256 WITH PEGINTERFERON-ALFA 2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 1 HCV PATIENTS by Nelson, D.R, Lawitz, E, Bain, V, Gitlin, N, Hawkins, T, Marotta, P, Workowski, K, Flamm, S, Pang, P.S, McHutchison, J.G, McNally, J, Urbanek, P, Yoshida, E.M

Get full text

Peritoneal dialysis after orthotopic liver transplant surgery by Apiratpracha, W, Chung, H V, Ali, J Al, Bashir, K, Yoshida, E M, Singh, R S

Get full text

Liver biochemistry abnormalities in a quaternary care lipid clinic database by Wiesinger, Holly A R, Shah, J, White, A, Yoshida, E M, Frohlich, J, Sirrs, S, Gill, S, Byrne, M F

“…The metabolic syndrome and non-alcoholic fatty liver disease are increasing at alarming rates. To determine the effect of HMG-CoA reductase inhibitors…”
Get full text

FRI-495 - The current state of liver transplantation in Canada by Yoshida, E.M., Thiele, S.L., Mason, A., Peltekian, K., Wong, P., Hux, M., Fischer, A., Borrelli, R.

Get full text

Stereotactic Body Radiotherapy for Large Unresectable Hepatocellular Carcinomas – A Single Institution Phase II Study by Beaton, L., Dunne, E.M., Yeung, R., Rackley, T., Weber, B., Mar, C., Yong-Hing, C.J., Yoshida, E.M., DeVries, K., Lee, R., Duzenli, C., Loewen, S.K., Liu, M., Schellenberg, D., Ma, R.

“…To evaluate the safety and efficacy of liver stereotactic body radiotherapy (SBRT) in the treatment of unresectable hepatocellular carcinomas (HCC) measuring…”
Get full text

“Another thing to live for”: Supporting HCV treatment and cure among Indigenous people impacted by substance use in Canadian cities by Pearce, M.E., Jongbloed, K., Demerais, L., MacDonald, H., Christian, W.M., Sharma, R., Pick, N., Yoshida, E.M., Spittal, P.M., Klein, M.B.

“…Colonization and colonial systems have led to the overrepresentation of Indigenous people impacted by substance use and HCV infection in Canada. It is critical…”
Get full text

SAT-246 - Are DAAs reducing barriers for HIV co-infected and people who inject drugs? A population based cohort study by Janjua, N., Islam, N., Wong, J., Yoshida, E.M., Ramji, A., Samji, H., Butt, Z.A., Chong, M., Cook, D., Alvarez, M., Tyndall, M., Krajden, M.

Get full text